BiomX Inc. Reports Q2 2025 Progress and Financials

Biomx Inc. ( (PHGE) ) has released its Q2 earnings. Here is a breakdown of the information Biomx Inc. presented to its investors.

BiomX Inc., a clinical-stage company, is pioneering the development of phage therapies targeting pathogenic bacteria to treat chronic diseases. In its latest earnings report for the second quarter of 2025, BiomX highlighted significant advancements in its clinical programs, particularly the positive Phase 2 results for BX211 in diabetic foot osteomyelitis and the commencement of a Phase 2b trial for BX004 in cystic fibrosis. The company reported a net loss of $6.0 million for the quarter, with a cash balance of $15.2 million, sufficient to fund operations into early 2026. Key achievements include a 40% reduction in wound size for BX211 and a 500-fold bacterial reduction for BX004, underscoring the potential of BiomX’s phage therapy platform. Looking ahead, BiomX is poised for further developments with anticipated FDA feedback and topline results from ongoing trials expected in the coming months, positioning the company for potential growth and value creation.